Skip to content
Motir
Start free

Ideas to build

Build what Motir would buy.

A software company runs on more than code. It needs a lawyer, an accountant, a security team and people who know other markets, and Motir is no different. We would rather buy that work from a product built on Motir. These are the ones we need. Build one that scales, and Motir will be your first customer.

A few sentences is enough. Motir asks about the rest.

Motir is your first customer

Build one of these on Motir, in public, and we will use it, pay for it and tell you what is missing.

What makes a good idea here

Products that scale, not tools for one team

  1. Many customers, one productEvery idea serves thousands of companies with the same problem, not one company's own process.
  2. Expertise you can't hire cheaplyLaw, tax, security, languages: work that needs a specialist, made affordable by AI and kept honest by people.
  3. A person still signsThe AI drafts, checks and files the work. A qualified person approves what carries risk, the same way Motir puts a person at every gate.

Find an idea

1 idea matches

All categoriesFamily care1Personal growth2Personal finance1Health & wellness1
Tags · 1 selected
AI agents4B2B software6Caregiving1Compliance10Consumers5Developer tools3Education2EU AI Act2Healthcare5China market3Latin America market1Pricing and billing2Small businesses9Startups2Vertical software6On YC's request list2
Filtered byCategory: Health & wellnessRemoveTag: ConsumersRemoveClear all

More directions · 1

Good products to build, beyond what Motir needs

Motir won't be your first customer for these. Each is a market with documented demand, a gap the current players leave open, and a reason it can be built now and not five years ago. The evidence is linked under each one.

  • Health & wellness

    A brand-neutral companion for people on weight-loss pens in Brazil

    For the millions of Brazilians on semaglutide or tirzepatide pens, now that cheaper Brazilian-made pens are reaching pharmacies. It keeps the prescription valid, tracks doses and side effects, guards against muscle loss, and compares prices across every brand's discount programme. Switching brands does not mean starting over.

    • Consumers
    • Healthcare
    • Latin America market
    The evidence
    Anvisa approved 14 new pens for diabetes and obesity in 2026 (10 semaglutide, 3 liraglutide, 1 tirzepatide), including EMS's Ozivy (26 May) and products from Cosmed, Ávita Care, Brainfarma, Sun, Ranbaxy and Germed. Ozempic costs R$975 to R$999; Ozivy launched at R$452 to R$498 per pen; generics must be at least 35% cheaper than the reference drug. Revista Oeste (pt)
    The gap
    Support in Brazil is tied to one brand. Novo Nordisk's NovoDia and NovoCare cover only Novo products, EMS's Vida + Leve covers only Ozivy, and Eurofarma prices its own pens. A patient who switches to a cheaper pen leaves one programme and starts another. Clinic programmes such as Liti sell full medical follow-up at clinic prices. None keeps one record across brands that tracks the retained 90-day prescription, dose steps, side effects and protein in Portuguese.
    +9 more sources

Build one. We'll be your first customer.

Start with the idea, plan it with Motir and build it in public. Pick one of these, or bring your own.

Start a project